The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?
Background: MS is a highly heterogeneous disease, both in its course and in its response to treatments. Effective biomarkers may help predict disability progression and monitor patients’ treatment responses. <br/>Objective: To focus on how biomarkers may contribute to treatment individualisat...
| Egile Nagusiak: | , , , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
SAGE Publications
2016
|